stockportfolio.pro
Stocks / NUTX vs PCRX
NUTX vs PCRX
Nutex Health Inc. and Pacira BioSciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Nutex Health Inc. (NUTX) | Pacira BioSciences, Inc. (PCRX) | |
|---|---|---|
| Market cap | $1.0B | $0.9B |
| Revenue (latest FY) | $875.26M | $726.41M |
| Net income (latest FY) | $70.79M | $7.03M |
| Revenue growth (5y CAGR) | 26.1% | 11.1% |
| Net margin | 8.1% | 1.0% |
| Return on equity | 21.5% | 1.0% |
| P/E ratio | 10.1 | 180.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 5 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NUTX — free Open PCRX — freeFrequently asked questions
Which is bigger, NUTX or PCRX?
Nutex Health Inc. is larger by market capitalization — $1.0B versus $0.9B.
Which grows faster, NUTX or PCRX?
Over the last five fiscal years, Nutex Health Inc. grew revenue faster — 26.1%/yr versus 11.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.